The abstract is read at the publisher; the summary is JClub's.
ChAdOx2 CCHF in UK healthy adults (18–55) showed acceptable tolerability and induced CCHFV glycoprotein-specific IgG responses, with median GP38 IgG rising to 1064·13 AU 28 days after dose two.
- Why it matters: No approved vaccines exist for Crimean-Congo haemorrhagic fever virus, a WHO priority pathogen, so early evidence on safety and immune responses is needed to guide further development.
- What they did: In an open-label, first-in-human, non-randomised phase 1 trial at Oxford, 46 adults received two intramuscular doses of ChAdOx2 CCHF 12 weeks apart; safety was assessed after vaccination and binding antibodies were measured at prespecified timepoints.
- The result: Solicited adverse events were mostly mild and no serious adverse events were reported; median CCHFV glycoprotein Gc-specific IgG reached 88·20 AU 28 days after the second dose, supporting proof of principle for further trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.